Researchers and industry leaders introduce emerging approaches being studied for advanced prostate cancer, including targeted immunotherapy, radioligand therapy and personalized treatment designed to activate the immune system against cancer.
The presenters explain how these investigational treatments are intended to identify prostate cancer cells more precisely, deliver therapy directly to tumors or help the body’s T cells recognize and attack cancer. They also discuss current study populations, early research findings and the questions these clinical trials are designed to answer.
Featured speakers:
Fouad Moussa, PhD — Johnson & Johnson
Sarah Nagle, MD — Johnson & Johnson
Aimal Ahmed, MD — Telix Pharmaceuticals
Charles Link, MD — Syncromune
The treatments discussed in this segment are investigational, and early study results may not predict results in larger trials. Patients should speak with their healthcare team about potential benefits, risks and eligibility. Explore clinical-trial opportunities at PHENTrials.com.